Tonix Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TNXP)

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Tonix Pharmaceuticals shares reverse split before market open on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.01. View Tonix Pharmaceuticals' Earnings History.

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Tonix Pharmaceuticals.

1 brokers have issued 1-year price targets for Tonix Pharmaceuticals' stock. Their forecasts range from $1.30 to $1.30. On average, they anticipate Tonix Pharmaceuticals' share price to reach $1.30 in the next twelve months. This suggests a possible upside of 182.6% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

Press coverage about TNXP stock has trended somewhat negative on Monday, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Tonix Pharmaceuticals.

Tonix Pharmaceuticals saw a decline in short interest in August. As of August 15th, there was short interest totalling 471,300 shares, a decline of 45.5% from the July 15th total of 864,500 shares. Based on an average daily volume of 555,700 shares, the short-interest ratio is presently 0.8 days. Approximately 20.3% of the company's stock are sold short. View Tonix Pharmaceuticals' Current Options Chain.

Some companies that are related to Tonix Pharmaceuticals include Aerpio Pharmaceuticals (ARPO), Fibrocell Science (FCSC), Zafgen (ZFGN), Mateon Therapeutics (MATN), Clearside Biomedical (CLSD), Seelos Therapeutics (SEEL), KemPharm (KMPH), Aileron Therapeutics (ALRN), AzurRx BioPharma (AZRX), Provectus Biopharmaceuticals (PVCT), Acerus Pharmaceuticals (TRLPF), ProPhase Labs (PRPH), OncoSec Medical (ONCS), Aytu Bioscience (AYTU) and Addex Therapeutics (ADDXF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Novavax (NVAX), SCYNEXIS (SCYX), Synthetic Biologics (SYN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR) and Rigel Pharmaceuticals (RIGL).

Tonix Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.55%), Acadian Asset Management LLC (0.43%) and A.R.T. Advisors LLC (0.20%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

TNXP stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNXP stock can currently be purchased for approximately $0.46.

Tonix Pharmaceuticals has a market capitalization of $7.23 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]